Abstract:Objective To identify the clinical features, the molecular diagnosis and the molecular mechanism of three unrelated factor X deficiency families. Methods Three probands were male and the diagnosis was validated by coagulant parameters. The F X coagulation activity ( F X∶ C ) and antigen (FX∶ Ag) were tested by clotting test and ELISA method. The cross-corrected test was used to rule out the inhibitor of FX in plasma. Thrombin generation test was evaluated. The antigen and the molecule weight of the FX in plasma were measured with western blotting. Gene mutations were analyzed in the probands and their family members with PCR and DNA sequencing. FX expression plasmids were constructed and transientby being transfected into 293T cells. FX: C and FX: Ag of the expression products were tested. Results APTT and PT in proband 1 were obviously prolonged, 113.4 s and 62.3 s, respectively. And there was no inhibitor in plasma. The thrombin generation was lower compared to normal reference. APTT and PT in proband 2 were 56. 5 s and 28.7 s. There was no inhibitor in the plasma. The thrombin generation was 1 101.5 nmol · min. APTT and PT in proband 3 were 117.3 s and 44. 3 s. The thrombin generation was 782.5 nmol · min. FX∶ C and FX∶ Ag in proband 1 were 1.4% and 3.6%, with a homozygous mutation in FX gene (Ser425→Pro). In vitro expression of the mutation showed a normal synthesis in the cell but secretion dysfuntion. In proband 2 F X: C and F X: Ag were 2. 2% and 5. 5%, with two heterozygous mutations in FX gene (Ala-29→Pro and Phe324→Leu). The Ala-29 → Pro mutation led to significantly reduced expressions of FX in both cell lysate and cell culture supernatants compared to wild-type plasmid,(41.32 ±5.21 )% and(6. 30 ± 1.84)% respectively. However Phe324→Leu mutation almost did not affect the FX synthesis. FX: C and FX: Ag in proband 3 were 2. 2% and 35%, with two heterozygous mutations in FX gene( Ala235→Thr and Arg347→Cys). The expressions of these two mutant FX proteins in cell lysate were similar to those of wild-type but obviously lower in the supernatant. Conclusions Five mutations of F X gene are found in this study. These mutations (Ser425Pro, Phe324Leu, Ala235Thr and Arg347Cys)can not affect F X protein synthesis. However Ala-29Pro mutation can reduce F X protein synthesis and cause secretion dysfunction.

Inherited factor X deficiency: molecular genetics and pathophysiology

Inherited factor VII deficiency: genetics and molecular pathology

Molecular analysis of the genotype-phenotype relationship in factor X deficiency

Clinical, Laboratory Aspects and Management of Factor X Deficiency

Molecular Defects in the Factor X Gene Caused by Novel Heterozygous Mutations IVS5+1G>A and Asp409del.

The Missense Thr211Pro Mutation in the Factor X Activation Peptide of a Bleeding Patient Causes Molecular Defect in the Clotting Cascade.

[Congenital Factor X Deficiency: a Retrospective Analysis of 11 Cases].

Molecular Basis of the Clotting Defect in a Bleeding Patient Missing the Asp-185 Codon in the Factor X Gene

Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys

Study on the molecular mechanism of the inherited factor X deficiency in three unrelated families

Roles of platelets and factor XI in the initiation of blood coagulation by thrombin

A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree

Inherited coagulation factor X deficiency caused by two novel mutations in factor X gene]

Structure–Function Relationship of the Interaction between Tissue Factor and Factor VIIa

Crystal Structure of Human Factor VIII: Implications for the Formation of the Factor IXa-Factor VIIIa Complex

Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis

Regulation of human coagulation factor X gene expression by GATA-4 and the Sp family of transcription factors

Advance in the Development of Factor Xa Inhibitors

Six novel missense mutations causing factor X deficiency and application of thrombin generation test.

Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports

The Disulfide Bond between Cys22 and Cys27 in the Protease Domain Modulate Clotting Activity of Coagulation Factor X.